Ultragenyx Pharmaceutical Inc. (RARE) Stock Grade

About Ultragenyx Pharmaceutical Inc.'s fundamentals

Ultragenyx Pharmaceutical is a biotechnology company with a market capitalization of $1.4 billion that is experiencing strong revenue growth at 20.1% year-over-year, indicating expanding business activity. However, the company operates at a significant loss, with a net margin of -85.4%, and reported a net loss in its latest annual statement, reflecting typical early-stage biotech dynamics where development and commercialization costs exceed revenues. The company does not pay a dividend, which is common for unprofitable firms prioritizing cash reinvestment into research and operations. The unusually high return on equity figure of 718.8% appears driven by the negative shareholder equity base associated with accumulated losses rather than operational profitability.